Naslov
DIGITAL THERAPY IN ONCOLOGY

Autori
Javor, Eugen

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Libri Oncologici : Croatian Journal of Oncology , Vol. 50 No. Supplement 2, 2022. / Milas, Ivan - Zagreb : Klinički bolnički centar Sestre milosrdnice, 2022, 17-17

Skup
1st Croatian Virtual Congress of Oncology Pharmacy

Mjesto i datum
Zagreb, Hrvatska, 07.10.2021. - 10.10.2021

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Domaća recenzija

Ključne riječi
digital therapy ; oncology ; accessibility ; improving outcomes

Sažetak
Introduction: DTx (Digital Therapeutics) products represent a new category of evidenced-based therapeutic technologies that support clinicians in the delivery of high-quality patient care and consequently improve patient outcomes. DTx delivers evidence-based therapies via software, like mobile health apps, that replace or complement the existing treatment of a disease. Last year (2020), Insider Intelligence expected the DTx space to hit nearly $9 billion by 2025, but its new forecasts expect DTx to be a $56 billion global opportunity by 2025. Methods: We have searched through scientific and professional literature for Digital Therapeutics and its effect on clinical outcomes and pharmacoeconomic analyses in oncology. Results: From all registered clinical trials over the past 10 years involving DTx around 6% are in oncology therapeutic area. Seventy-seven percent of DTx trials have been sponsored by academia, but there is trend in increase in industry sponsored trials. To address the challenge posed by adaptive software- as-a-medical-device (SaMD) products, the US Food & Drug Administration (FDA) released a discussion paper in April 2019, describing a possible regulatory approach for premarket review regarding machine-learning-driven modifications in SaMD. Cross- industry stakeholders at the Digital Medicine Society (DiMe) and the FDA synthesized best practices from the digital health field, and created The Playbook, the comprehensive and accessible how-to guide to support all stakeholders working to advance the safe, effective, ethical, and equitable use of digital clinical measures to improve outcomes. Nevertheless, besides regulatory advancements in the DTx area the most important benefit of DTx are its effect on the patient centred outcomes. DTx prolonged overall survival in cancer patients with metastatic solid tumors and nonprogressive patients treated for metastatic lung cancers. Conclusion: DTx emerge as great technologies that can directly impact disease state measures and clinical outcomes, expand access to safe, confidential, and effective medical treatments, extend clinicians’ ability to care for patients, maximize patient engagement, and lower overall healthcare costs. Because of their easy accessibility, record of improving outcomes and ability to integrate into care management workflows, DTx products are becoming critically important tools for the healthcare

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA